Clinical Trial Update: CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating CS1008 in combination with sorafenib versus sorafenib alone in advanced liver cancer has completed recruitment with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Cancer
• Hepatocellular Carcinoma
• Liver Cancer
• Liver Neoplasms

Drugs mentioned

• CS1008 (investigational) (CS1008)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Advanced Hepatocellular Carcinoma, Liver Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-04-08